FDA Panel Narrowly Endorses AtriCure’s Synergy For A-Fib Ablation
This article was originally published in The Gray Sheet
Executive SummaryFDA’s Circulatory System Devices panel narrowly endorsed an expanded indication last week for AtriCure’s Synergy ablation system to treat certain types of atrial fibrillation during open-heart surgery, despite concerns over safety issues and limited data.
You may also be interested in...
AtriCure’s Synergy surgical ablation system for atrial fibrillation and J&J/DePuy’s next-generation polyethylene bearing for rotating platform and mobile bearing knees gain PMA approvals. More new products.
Atrial fibrillation treatments involving standalone surgical ablation and catheter ablation were discussed in data presentations at the American Heart Association annual meeting last week.